Tahar Hajri1, Mohamed Gharib, Sanjeev Kaul, Martin S Karpeh. 1. From the Department of Surgery (T.H., M.G., M.S.K.) and Trauma/Surgical Critical Care and Injury Prevention Unit (S.K.), Hackensack University Medical Center, Hackensack, New Jersey.
Abstract
BACKGROUND: Adipose tissue is an endocrine organ that plays a critical role in immunity and metabolism by virtue of a large number of hormones and cytokines, collectively termed adipokines. Dysregulation of adipokines has been linked to the pathogenesis of multiple diseases, but some questions have arisen concerning the value of adipokines in critical illness setting. The objective of this review was to evaluate the associations between blood adipokines and critical illness outcomes. METHODS: PubMed, CINAHL, Scopus, and the Cochrane Library databases were searched from inception through July 2016 without language restriction. Studies reporting the associations of adipokines, leptin, adiponectin, resistin, and/or visfatin with critical illness outcomes mortality, organ dysfunction, and/or inflammation were included. RESULTS: A total of 38 articles were selected according to the inclusion/exclusion criteria of the study. Significant alterations of circulating adipokines have been reported in critically ill patients, some of which were indicative of patient outcomes. The associations of leptin and adiponectin with critical illness outcomes were not conclusive in that blood levels of both adipokines did not always correlate with the illness severity scores or risks of organ failure and mortality. By contrast, studies consistently reported striking increase of blood resistin and visfatin, independently of the critical illness etiology. More interestingly, increased levels of these adipokines were systematically associated with severe inflammation, and high incidence of organ failure and mortality. CONCLUSIONS: There is strong evidence to indicate that increased levels of blood resistin and visfatin are associated with poor outcomes of critically ill patients, including higher inflammation, and greater risk of organ dysfunction and mortality. LEVEL OF EVIDENCE: Systematic review, level III.
BACKGROUND: Adipose tissue is an endocrine organ that plays a critical role in immunity and metabolism by virtue of a large number of hormones and cytokines, collectively termed adipokines. Dysregulation of adipokines has been linked to the pathogenesis of multiple diseases, but some questions have arisen concerning the value of adipokines in critical illness setting. The objective of this review was to evaluate the associations between blood adipokines and critical illness outcomes. METHODS: PubMed, CINAHL, Scopus, and the Cochrane Library databases were searched from inception through July 2016 without language restriction. Studies reporting the associations of adipokines, leptin, adiponectin, resistin, and/or visfatin with critical illness outcomes mortality, organ dysfunction, and/or inflammation were included. RESULTS: A total of 38 articles were selected according to the inclusion/exclusion criteria of the study. Significant alterations of circulating adipokines have been reported in critically illpatients, some of which were indicative of patient outcomes. The associations of leptin and adiponectin with critical illness outcomes were not conclusive in that blood levels of both adipokines did not always correlate with the illness severity scores or risks of organ failure and mortality. By contrast, studies consistently reported striking increase of blood resistin and visfatin, independently of the critical illness etiology. More interestingly, increased levels of these adipokines were systematically associated with severe inflammation, and high incidence of organ failure and mortality. CONCLUSIONS: There is strong evidence to indicate that increased levels of blood resistin and visfatin are associated with poor outcomes of critically illpatients, including higher inflammation, and greater risk of organ dysfunction and mortality. LEVEL OF EVIDENCE: Systematic review, level III.
Authors: Pavel Skorepa; Ondrej Sobotka; Jan Vanek; Alena Ticha; Joao Fortunato; Jan Manak; Vladimir Blaha; Jan M Horacek; Lubos Sobotka Journal: Nutrients Date: 2020-05-11 Impact factor: 5.717
Authors: Kürşat Gündoğan; Ender Doğan; Nurhayat Tuğra Özer; Gülşah Güneş Şahin; Serap Şahin; Murat Sungur; Ismail Hakki Akbudak; Sabahattin Muhtaroğlu; Muhammet Güven; Thomas R Ziegler Journal: Turk J Med Sci Date: 2020-04-27 Impact factor: 0.973
Authors: Mark Luedde; Martina E Spehlmann; Hans-Joerg Hippe; Sven H Loosen; Sanchari Roy; David Vargas Cardenas; Mihael Vucur; Norbert Frey; Alexander Koch; Tom Luedde; Christian Trautwein; Frank Tacke; Christoph Roderburg Journal: PLoS One Date: 2018-10-17 Impact factor: 3.240
Authors: Liangjie Xu; Tianxin Geng; Guangyao Zang; Li Bo; Yi Liang; Hong Zhou; Jinchuan Yan Journal: J Cell Mol Med Date: 2020-03-09 Impact factor: 5.310
Authors: Alexander Koch; Ralf Weiskirchen; Alexander Krusch; Jan Bruensing; Lukas Buendgens; Ulf Herbers; Eray Yagmur; Ger H Koek; Christian Trautwein; Frank Tacke Journal: Dis Markers Date: 2018-08-26 Impact factor: 3.434
Authors: Vidisha Raje; Katelyn W Ahern; Brittany A Martinez; Nancy L Howell; Vici Oenarto; Mitchell E Granade; Jae Woo Kim; Smanla Tundup; Katharina Bottermann; Axel Gödecke; Susanna R Keller; Alexandra Kadl; Michelle L Bland; Thurl E Harris Journal: Sci Rep Date: 2020-10-23 Impact factor: 4.379